Why women look for peptides for the heart
Midlife is when cholesterol and blood pressure start getting a closer look at the yearly checkup. It's also when looking after the heart you have, before anything needs treating, starts to sound like a sensible plan.
The research peptides sold mainly with that in mind are SS-31, Cardiogen and Vesugen. SS-31 aims at mitochondria, the parts of each cell that make energy, and heart muscle is packed with them, so it's sold for stamina and healthy aging with the heart in the frame. Cardiogen and Vesugen come from the Russian Khavinson bioregulator family, short peptides matched organ by organ like a very small seating chart, with Cardiogen assigned to the heart and Vesugen to blood vessels. The protocol pages and community sites that describe them give both as short courses repeated after months off, as part of a healthy-aging routine.
How SS-31, Cardiogen and Vesugen compare
| Peptide | Sold for | Research so far |
|---|---|---|
| SS-31 | Stamina, healthy aging, heart and muscle | Cells, aged mice, human trials (no benefit in the heart ones) |
| Cardiogen | Heart support with age | Cells and rodents, one Russian group |
| Vesugen | Circulation, blood vessel aging | Mostly cells and animals, one Russian group |
SS-31 has the most research of the three. In aged mice, it reduced age-related damage to heart proteins. In people, two heart trials came up empty: a heart failure trial saw no change in the measure it tracked, and a heart attack trial didn't shrink the damage it measured. Its one approved use isn't a heart use. In September 2025 the FDA gave it accelerated approval (a faster approval that comes with a follow-up trial to confirm it) as Forzinity, to improve muscle strength in Barth syndrome, a rare inherited mitochondrial disease, for adults and children weighing at least 66 pounds.
Cardiogen's research is lab dishes, where it encouraged heart muscle cells to grow while holding back the cells that lay down scar tissue, and rodents given an induced heart injury, which had smaller areas of damage. All of it comes from one research group, and no human trial has been published. Vesugen's work is similar in shape, with cell studies on the lining of blood vessels, a good deal of brain-cell research, and a few small studies in older adults from its own developers that nobody else has repeated.
Where semaglutide and tirzepatide fit
Two prescription drugs are peptides too. In a large trial of people with overweight and heart disease but no diabetes, semaglutide cut heart attacks, strokes and heart-related deaths by about a fifth, and Wegovy's label now includes lowering that risk. In a trial of people with obesity and the stiff-heart type of heart failure, the kind where the heart squeezes normally but doesn't relax and fill well, tirzepatide cut the combined risk of heart-related death or worsening heart failure, mostly through fewer episodes of heart failure getting worse. Our semaglutide vs. tirzepatide page sets the two side by side.
If you're choosing one
Start with what you want it for. If it's energy and stamina you're after, SS-31 is the one people buy for it, though no trial has tested it for that in healthy people yet. The SS-31 dosage page sets out the amounts with their sources. If you're drawn to the bioregulator idea, the Cardiogen dosage page and Vesugen dosage page cover the short courses people run. We track 25 vendors with a live SS-31 listing, 12 for Cardiogen and 7 for Vesugen, so compare the price per milligram rather than the vial, and look for a recent third-party certificate of analysis for the batch. How to read a COA walks through one, and the vendor directory shows how each seller scores.
Semaglutide and tirzepatide have labels and prescribers behind them, and SS-31 has a label for one rare disease, but a vial of any of these bought from a research vendor is sold for research. You knew that, it's why you're reading this and not the label.
Questions people ask
Is there a peptide for heart failure?
Tirzepatide, a prescription drug, cut the combined risk of heart-related death or worsening heart failure in a trial of people with obesity and the stiff-heart type of heart failure, mostly through fewer flare-ups of heart failure. SS-31 was tested in a heart failure trial, and it made no difference to the measure the trial tracked.
What is the best peptide for heart health?
There's no single best one, it comes down to what you want it for. People buy SS-31 for energy with the heart in mind, and it has the most research of the three, including human trials, while Cardiogen and Vesugen are the Russian bioregulators taken in short courses for the heart and blood vessels. Semaglutide and tirzepatide are the best-known prescription peptides with heart trials that found a benefit.
Does Cardiogen affect blood pressure?
No published study has measured Cardiogen's effect on blood pressure in people or animals, so nobody knows whether it changes it at all. Anyone who already takes blood pressure medication is in untested territory with it.
Can you take Cardiogen or Vesugen with heart medication?
Cardiogen has never been tested alongside blood pressure medication, blood thinners, statins or heart rhythm drugs, and it isn't a stand-in for any of them. The same gap applies to Vesugen, which has no human data for people on blood thinners or blood pressure medicine.
Is SS-31 FDA approved for the heart?
No. Under the brand name Forzinity, it has accelerated approval, a faster approval that needs a follow-up trial to confirm it, for one use, improving muscle strength in Barth syndrome, a rare inherited disease. Any heart use is unapproved.
